Recent decline observed in high grade cervical lesions

(HealthDay) – The number of cervical precancers (CIN2 + case) in the United States has decreased from 2008 to 2016, probably in part because of prevention with the human papillomavirus (HPV) vaccine, according to a published study in the US edition of April 19. Centers for Disaster Control and Prevention Weekly report on morbidity and mortality.

Nancy M. McClung, Ph.D., of the CDC of Atlanta, and her colleagues badyzed the data from the project to monitor the impact of the vaccine against the human papillomavirus, a CIN2 + surveillance system in population, in order to characterize CIN2 + rates in women aged 18 or older from 2008 to 2016.

The researchers found that between 2008 and 2016, the rate of CIN2 + per 100,000 women had significantly decreased in women aged 18 to 19 and between 20 and 24, but had increased significantly in women 40 to 64 years old. In 2008, about 216,000 American women were diagnosed with CIN2 +, of which more than half (55%) were women aged 18 to 29 years. In comparison, in 2016, approximately 196,000 cases of CIN2 + were diagnosed, of which more than one-third (36%) involved women aged 18 to 29 years. During the study period, approximately three-quarters of CIN2 + cases (76%) were attributable to HPV types targeted by the vaccine currently used in the United States.

"These CIN2 + case estimates likely reflect changes in the detection of CIN2 + resulting from updated cervical cancer screening and management recommendations, as well as from primary prevention through HPV vaccination. ", write the authors.

Copyright © 2019 HealthDay. All rights reserved.